Alfacell sees positive Onconase results |
|
|
|
Published
:
Mon, 16 Apr 2007 20:34
|
BLOOMFIELD, N.J. (AP) - Biotechnology company Alfacell Corp. said Monday preclinical studies of its developing drug Onconase showed it has potential in fighting tumors in non-small cell lung cancer and breast cancer.The drug is already in late-stage clinical development for malignant mesothelioma, a rare form of cancer found in the chest, abdominal cavity lining or the lining around the heart.Shares of Alfacell jumped 41 cents, or 16.9 percent, to $2.91 on the Nasdaq Stock Market in afternoon trading. The stock has traded between 73 cents and $3.94 over the last 52 weeks.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
Print this Story
Amsterdam shares AFX at a glance outlook 